c-MET (D1228V)

MET · Variant type: point · HGVS: p.D1228V

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	91.2%	8.8%	88.97
2	Pacritinib	70.3%	29.7%	88.64
3	Tivozanib	69.7%	30.3%	92.42
4	Defactinib	69.1%	30.9%	92.68
5	Neratinib	57.6%	42.4%	93.18
6	Repotrectinib	56.7%	43.3%	84.21
7	Selpercatinib	43.5%	56.5%	96.72
8	Canertinib	30.5%	69.5%	96.49
9	Sunitinib	29.8%	70.2%	91.73
10	Fedratinib	27.4%	72.6%	96.21
11	Tepotinib	24.7%	75.3%	99.75
12	Abemaciclib	19.4%	80.6%	91.48
13	Entrectinib	16.5%	83.5%	93.69
14	Capmatinib	14.4%	85.6%	99.75
15	Avapritinib	13.0%	87.0%	97.73
16	Rabusertib	11.2%	88.8%	98.74
17	Infigratinib	10.6%	89.4%	98.24
18	Pexidartinib	9.4%	90.6%	99.49
19	Selumetinib	8.8%	91.2%	100.00
20	Erdafitinib	8.3%	91.7%	95.71
21	Erlotinib	7.9%	92.1%	99.75
22	Pirtobrutinib	6.8%	93.2%	99.49
23	Umbralisib	6.3%	93.8%	98.74
24	Paxalisib	5.9%	94.1%	99.75
25	Ripretinib	5.0%	95.0%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	91.2%	—	—
Pacritinib	70.3%	—	—
Tivozanib	69.7%	—	—
Defactinib	69.1%	—	—
Neratinib	57.6%	—	—
Repotrectinib	56.7%	—	—
Selpercatinib	43.5%	—	—
Canertinib	30.5%	—	—
Sunitinib	29.8%	—	—
Fedratinib	27.4%	—	—
Tepotinib	24.7%	—	—
Abemaciclib	19.4%	—	—
Entrectinib	16.5%	—	—
Capmatinib	14.4%	—	—
Avapritinib	13.0%	—	—
Rabusertib	11.2%	—	—
Infigratinib	10.6%	—	—
Pexidartinib	9.4%	—	—
Selumetinib	8.8%	—	—
Erdafitinib	8.3%	—	—
Erlotinib	7.9%	—	—
Pirtobrutinib	6.8%	—	—
Umbralisib	6.3%	—	—
Paxalisib	5.9%	—	—
Ripretinib	5.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 27.7ms